4D Molecular Therapeutics Inc. (FDMT) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for 4D Molecular Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$12.93
+8.11% today
Market cap
$661M
Overall quality
49/100
Kronos AI 30-day
−1.0%
4 of 8 simulated paths end higher
4D Molecular Therapeutics Inc. (FDMT) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $661M. It trades at $12.93, up 8.11% today. Its overall quality score is 49 out of 100, ranked against the whole US market. 7 analysts' average target of $30.57 implies +136.4% from today's price. Kronos AI's 30-day forecast is −1.0% (4 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $30.57 |
| Low – high | $20.00 – $37.00 |
| Analysts | 7 |
| Upside to average | +136.4% |
Kronos AI 30-day forecast
| Expected close | $11.84 (−1.0%) |
| Likely range | −17.2% … +17.9% |
| As of | 2026-10-27 |
4 of 8 simulated paths end higher.
Quality scores
| Profitability | 13 |
| Solvency | 56 |
| Growth | 78 |
| Overall | 49 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.